RT-200 (Ucn2)

About Renova Therapeutics

Renova Therapeutics is a private, San Diego-based biotech founded in 2009, pioneering gene therapies for congestive heart failure and type 2 diabetes. The company's platform leverages AAV vectors to deliver therapeutic genes, with its lead candidate RT-100 (AC6 gene therapy) for heart failure and RT-200 (Urocortin-2 gene therapy) for type 2 diabetes advancing through clinical development. Renova has gained regulatory recognition in the UK via Innovation Passports for both programs and has secured NIH grant funding, positioning it to address massive, underserved chronic disease markets with a one-time treatment paradigm.

Therapeutic Areas